Clinical trial

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509

StatusENROLLING_BY_INVITATION

Study typeINTERVENTIONAL

Start date2024-12-30

PhasePHASE1

Study timeline

Study start (actual)2024-12-30Date precision: day

Registry last updated2026-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Leukemia, Myeloid, Acuteunresolved

Leukemia, Lymphocytic, Chronic, B-Cellunresolved

Lymphoma, Non-Hodgkinunresolved

Myelodysplastic Syndromesunresolved

Neoplasmsunresolved

Solid Tumor, Adultunresolved

Prostatic Neoplasms, Castration-Resistantunresolved

Interventions

JNJ-75348780DRUG

JNJ-67856633DRUG

JNJ-54179060DRUG

JNJ-64264681DRUG

JNJ-74856665DRUG

JNJ-70218902DRUG

JNJ-64619178DRUG

JNJ-80948543DRUG

JNJ-87801493DRUG

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

BarcelonaSpain3 HaifaIsrael3 MadridSpain2 SeoulSouth Korea1 LondonUnited Kingdom1 TaipeiTaiwan1 LilleFrance1 KrakowPoland1 TaichungTaiwan1 AthensGreece1 NantesFrance1 JerusalemIsrael1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06788509 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.